You are here: Industry Insights > Benlysta

News List

China grants approval to GSK’s Benlysta for lupus nephritis treatment Pharmaceutical-Technology
February 14, 2022
China’s National Medical Products Administration (NMPA) has granted approval to GlaxoSmithKline’s (GSK) Benlysta (belimumab) to treat active lupus nephritis (LN) in adults.
NICE turns down GSK's IV Benlysta for systemic lupus pharmatimes
June 04, 2021
The National Institute for Health and Care Excellence (NICE) has rejected NHS funding for an intravenous formulation of GlaxoSmithKline's Benlysta (belimumab) as an add-on therapy for certain patients with active autoantibody-positive systemic lupus.
Experimental Treatment Offers New Hope Against Lupus drugs
May 31, 2021
An experimental antibody therapy may help ease skin symptoms from the autoimmune disease lupus, a small preliminary trial suggests.
EC clears GSK's Benlysta for lupus nephritis pharmatimes
May 07, 2021
The European Commission approved expanded use of GlaxoSmithKline’s intravenous and subcutaneous Benlysta (belimumab) in combination with background immunosuppressive therapies for adults with active lupus nephritis (LN).
GSK gets FDA nod for Benlysta to treat adult patients with active lupus nephritis pharmaceutical-business-review
December 21, 2020
GlaxoSmithKline (GSK) has secured approval from the US Food and Drug Administration (FDA) for its Benlysta (belimumab) to treat adult patients with active lupus nephritis (LN) who are securing standard therapy.
GSK gets positive CHMP opinion for intravenous Benlysta biospectrumasia
September 25, 2019
European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) recommends approval of GSK's IV Benlysta in children with lupus aged five years and above
GSK trials Benlysta/rituximab combo for lupus pharmatimes
July 23, 2018
GlaxoSmithKline has kicked off a Phase III trial assessing its lupus drug Benlysta in combination with rituximab in adult patients with the condition.
EMA grants marketing authorisation for subcutaneous formulation of Benlysta against lupus europeanpharmaceuticalreview
November 16, 2017
The EU has approved a new subcutaneous formulation of Benlysta, as an add-on therapy in adult patients with active autoantibody-positive systemic lupus erythematosus…
GSK’s Benlysta receives Japanese MHLW approval for systemic lupus erythematosus pharmaceufical-technology
September 30, 2017
Indicated for patients who are inadequate responders to existing therapies, Benlysta is approved for use as an add-on therapy in autoantibody-positive SLE patients.